ClinicalTrials.gg
CompletedNCT00454779Updated Oct 17, 2018Results posted

PARTNER: Panitumumab Added to Regimen for Treatment of Head aNd Neck Cancer Evaluation of Response

A Phase 2 interventional study of Cisplatin and Panitumumab in Metastatic or Recurrent Squamous Cell Carcinoma of Head and Neck, sponsored by Amgen. Completed at 114 sites in 9 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2018-10-17.

Sponsored by Amgen · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
113
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies testing panitumumab in Neoplasm Metastasis — 1 open to participants now, 2 under way, none of them phase 3. Panitumumab · Neoplasm Metastasis.

Enrollment
11th of 19
113 · median 116
Started
2007
with 1 other
Phase 2
17 of 20
1 open now
Registered
11th of 20
by date
Lead sponsor
14 of 20
Amgen

Among the 20 studies testing panitumumab in Neoplasm Metastasis, this one is the 11th largest by enrollment of the 19 interventional ones that give a count, is one of 2 that started in 2007, is one of 17 in phase 2, and was the 11th registered.

Neoplasm Metastasis

4,048 studies on the registry are indexed under Neoplasm Metastasis; 891 are open to participants now.

Browse Neoplasm Metastasis studies →

Open to participants now

1 of the 20 studies testing panitumumab in Neoplasm Metastasis is open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

About panitumumab

Panitumumab: first FDA approval 2006 (VECTIBIX), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 691 Neoplasm Metastasis studies recruiting now, 538 (78%) set no upper age limit and 97 (14%) stop at 75 or younger; 48 take children under 18; 18 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing panitumumab in Neoplasm Metastasis, or all of them as a file.
02

Study summary

This is a randomized, open-label, 2-arm, controlled, phase 2, multi-center, estimation clinical trial of docetaxel and cisplatin combination chemotherapy with and without panitumumab in the first-line treatment of subjects with metastatic or recurrent head and neck cancer, as well as a cross-over second-line panitumumab monotherapy of subjects who fail the chemotherapy only arm. This study will be conducted in the United States. Approximately 150 subjects with histologically or cytologically confirmed metastatic and/or recurrent SCCHN.

03

Conditions studied

  • Metastatic or Recurrent Squamous Cell Carcinoma of Head and Neck

Keywords

  • SCCHNC
  • Metastatic
  • Recurrent
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • or cytologically confirmed and/or recurrent Squamous Cell Carcinoma of Head and Neck (SCCHN) determined to be incurable by surgery and/or radiation therapy.
  • by CT scan
  • (ECOG) performance score of 0 or 1
  • Age: 18 years or older
  • Adequate hematologic, renal, metabolic, hepatic \& thyroid function

Exclusion criteria

Exclusion Criteria:

  • Prior systemic treatment for and/or recurrent SCCHN
  • , or nasopharyngeal carcinoma
  • History of interstitial lung disease
  • History of another primary cancer
  • Any co-morbid disease that would increase risk of toxicity

    • Active infection requiring systemic treatment
    • Prior anti-Epidermal Growth Factor receptor (anti-EGFr) antibody therapy
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
113 participants (actual)

Study arms

  • Experimental
    Arm 1

    Panitumumab + Docetaxel + Cisplatin

    Drug: Panitumumab · Drug: Cisplatin · Drug: Docetaxel

  • Other
    Arm 2

    control

    Drug: Cisplatin · Drug: Docetaxel

Interventions

06

What researchers measure

Primary outcomes

  1. Progression Free Survival (PFS) During the First-line Treatment Phase

    The time from the date of randomization to the date of first disease progression determined by the investigators per modified RECIST v1.0, or death within 60 days after the last evaluable tumor assessment or randomization date (whichever is later) during the first-line treatment phase.

    Time frame: Every 6 weeks until disease progression or death, up to 67 months

Secondary outcomes

  1. Overall Response Rate (ORR) During the First-line Treatment Phase

    Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter (SLD) of target lesions from baseline; Overall Response (OR) = CR + PR. An overall response of CR or PR must be confirmed at least 4 weeks after the criteria for response are first met. ORR is the percentage of subjects with an overall response among the analysis population.

    Time frame: Every 6 weeks until disease progression or death, up to 67 months

  2. Rate of Disease Control (RDC) During the First-line Treatment Phase

    Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter (SLD) of target lesions from baseline; Disease Progression (PD), \>=20% increase in the SLD of target lesions from nadir; Stable Disease (SD), Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD. An overall response of CR or PR must be confirmed at least 4 weeks after the criteria for response are first met. A best overall response of SD requires a visit response of SD or better no earlier than 35 days after randomization. RCD is the percentage of subjects with a best overall response of CR, PR or SD among the analysis population.

    Time frame: Every 6 weeks until disease progression or death, up to 67 months

  3. Duration of Response (DOR) During the First-line Treatment Phase

    Calculated only for the subset of subjects who have an overall response of CR or PR while on first-line treatment phase (subsequently confirmed at least 4 weeks thereafter), and is defined as time from the first CR or PR to the first observed disease progression by a modified RECIST v1.0. Subjects not meeting the criteria for progression by the analysis data cutoff date will be censored at their last evaluable disease assessment date.

    Time frame: Every 6 weeks until disease progression or death, up to 67 months

  4. Time to Response (TTR) During the First-line Treatment Phase

    Time from the date of randomization to the first CR or PR during first line treatment phase (subsequently confirmed at least 4 weeks thereafter)

    Time frame: Every 6 weeks until disease progression or death, up to 67 months

  5. Overall Survival (OS) for the First-line Treatment

    Time from the date of randomization to the date of death during the entire study

    Time frame: Until death, up to 67 months

  6. Progression Free Survival (PFS) During the Second-line Treatment Phase

    The time from the first dose of panitumumab monotherapy to the date of first disease progression determined by the investigators per modified RECIST v1.0, or death within 60 days after the last evaluable tumor assessment or the second-line first dose date (whichever is later) during the second-line treatment phase.

    Time frame: Every 6 weeks until disease progression or death, up to 57 months

  7. Overall Response Rate (ORR) During the Second-line Treatment Phase

    Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter (SLD) of target lesions from baseline; Overall Response (OR) = CR + PR. An overall response of CR or PR must be confirmed at least 4 weeks after the criteria for response are first met. ORR is the percentage of subjects with an overall response among the analysis population.

    Time frame: Every 6 weeks until disease progression or death, up to 57 months

  8. Rate of Disease Control (RDC) During the Second-line Treatment Phase

    Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter (SLD) of target lesions from baseline; Disease Progression (PD), \>=20% increase in the SLD of target lesions from nadir; Stable Disease (SD), Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD. An overall response of CR or PR must be confirmed at least 4 weeks after the criteria for response are first met. A best overall response of SD requires a visit response of SD or better no earlier than 35 days after the first dose date in second-line treatment. RCD is the percentage of subjects with a best overall response of CR, PR or SD among the analysis population.

    Time frame: Every 6 weeks until disease progression or death, up to 57 months

  9. Duration of Response (DOR) During the Second-line Treatment Phase

    Time from the first CR or PR to the first observed disease progression by a modified RECIST v1.0. Subjects not meeting the criteria for progression by the analysis data cutoff date will be censored at their last evaluable disease assessment date.

    Time frame: Every 6 weeks until disease progression or death, up to 57 months

  10. Time to Response (TTR) During the Second-line Treatment Phase

    Time from the first dose of panitumumab monotherapy to the first CR or PR during second-line treatment phase (subsequently confirmed at least 4 weeks thereafter)

    Time frame: Every 6 weeks until disease progression or death, up to 57 months

  11. Overall Survival (OS) for the Second-line Treatment

    Time from the first dose of panitumumab monotherapy to the date of death during the entire study

    Time frame: Until death, up to 57 months

07

Results

Posted Feb 7, 2014

Participant flow

Subjects were enrolled from 29 January 2007 to 1 September 2010.

First-line Treatment Phase
Participant flow — First-line Treatment Phase
MilestonePanitumumab Plus ChemotherapyChemotherapy Alone
Started5657
Received study medication5655
Completed5149
Not completed58
Withdrew: Lack of efficacy02
Withdrew: Withdrawal by subject24
Withdrew: Lost to follow-up10
Withdrew: Protocol violation01
Withdrew: Ended follow-up prior to analysis11
Withdrew: Ongoing10
Second-line Treatment Phase
Participant flow — Second-line Treatment Phase
MilestonePanitumumab Plus ChemotherapyChemotherapy Alone
Started030
Completed027
Not completed03
Withdrew: Withdrawal by subject01
Withdrew: Ended follow-up prior to analysis01
Withdrew: Ongoing01

Outcome measures

PrimaryProgression Free Survival (PFS) During the First-line Treatment Phase

The time from the date of randomization to the date of first disease progression determined by the investigators per modified RECIST v1.0, or death within 60 days after the last evaluable tumor assessment or randomization date (whichever is later) during the first-line treatment phase.

Time frame:
Every 6 weeks until disease progression or death, up to 67 months
Reported as:
Median · Months
Progression Free Survival (PFS) During the First-line Treatment Phase
MonthsPanitumumab Plus ChemotherapyChemotherapy Alone
Progression Free Survival (PFS) During the First-line Treatment Phase6.9 (4.7 to 8.3)5.5 (4.1 to 6.8)
Statistical analysis
  • Panitumumab Plus Chemotherapy vs Chemotherapy Alone · Regression, Cox · p = 0.051 · Hazard ratio (hr): 0.629 · 95% CI 0.395 to 1.002Hazard ratio is presented as panitumumab plus chemotherapy:chemotherapy alone.
  • Panitumumab Plus Chemotherapy vs Chemotherapy Alone · Log Rank · p = 0.048Stratified by IVRS randomization factors
SecondaryOverall Response Rate (ORR) During the First-line Treatment Phase

Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter (SLD) of target lesions from baseline; Overall Response (OR) = CR + PR. An overall response of CR or PR must be confirmed at least 4 weeks after the criteria for response are first met. ORR is the percentage of subjects with an overall response among the analysis population.

Time frame:
Every 6 weeks until disease progression or death, up to 67 months
Reported as:
Mean · Percentage of Participants
Overall Response Rate (ORR) During the First-line Treatment Phase
Percentage of ParticipantsPanitumumab Plus ChemotherapyChemotherapy Alone
Overall Response Rate (ORR) During the First-line Treatment Phase44.23 (30.73 to 57.73)37.25 (23.99 to 50.52)
Statistical analysis
  • Panitumumab Plus Chemotherapy vs Chemotherapy Alone · Mean difference (final values): 6.23 · 95% CI -11.67 to 24.12With Mantel-Haenszel weights within strata defined by randomization factors recorded in the IVRS
  • Panitumumab Plus Chemotherapy vs Chemotherapy Alone · Odds ratio (or): 1.37 · 95% CI 0.57 to 3.33Calculated from a logistic regression model with treatment indicator and randomization factors (recorded on the CRF) as covariates
SecondaryRate of Disease Control (RDC) During the First-line Treatment Phase

Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter (SLD) of target lesions from baseline; Disease Progression (PD), \>=20% increase in the SLD of target lesions from nadir; Stable Disease (SD), Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD. An overall response of CR or PR must be confirmed at least 4 weeks after the criteria for response are first met. A best overall response of SD requires a visit response of SD or better no earlier than 35 days after randomization. RCD is the percentage of subjects with a best overall response of CR, PR or SD among the analysis population.

Time frame:
Every 6 weeks until disease progression or death, up to 67 months
Reported as:
Mean · Percentage of Participants
Rate of Disease Control (RDC) During the First-line Treatment Phase
Percentage of ParticipantsPanitumumab Plus ChemotherapyChemotherapy Alone
Rate of Disease Control (RDC) During the First-line Treatment Phase80.77 (70.06 to 91.48)72.55 (60.30 to 84.80)
Statistical analysis
  • Panitumumab Plus Chemotherapy vs Chemotherapy Alone · Mean difference (final values): 7.78 · 95% CI -8.29 to 23.85With Mantel-Haenszel weights within strata defined by randomization factors recorded in the IVRS
  • Panitumumab Plus Chemotherapy vs Chemotherapy Alone · Odds ratio (or): 1.76 · 95% CI 0.62 to 5.26Calculated from a logistic regression model with treatment indicator and randomization factors (recorded on the CRF) as covariates
SecondaryDuration of Response (DOR) During the First-line Treatment Phase

Calculated only for the subset of subjects who have an overall response of CR or PR while on first-line treatment phase (subsequently confirmed at least 4 weeks thereafter), and is defined as time from the first CR or PR to the first observed disease progression by a modified RECIST v1.0. Subjects not meeting the criteria for progression by the analysis data cutoff date will be censored at their last evaluable disease assessment date.

Time frame:
Every 6 weeks until disease progression or death, up to 67 months
Reported as:
Median · Months
Duration of Response (DOR) During the First-line Treatment Phase
MonthsPanitumumab Plus ChemotherapyChemotherapy Alone
Duration of Response (DOR) During the First-line Treatment Phase8.0 (5.7 to 11.1)5.1 (4.4 to 7.2)
SecondaryTime to Response (TTR) During the First-line Treatment Phase

Time from the date of randomization to the first CR or PR during first line treatment phase (subsequently confirmed at least 4 weeks thereafter)

Time frame:
Every 6 weeks until disease progression or death, up to 67 months
Reported as:
Mean · Weeks
Time to Response (TTR) During the First-line Treatment Phase
WeeksPanitumumab Plus ChemotherapyChemotherapy Alone
Time to Response (TTR) During the First-line Treatment Phase8.8 ± 3.910.6 ± 6.1
SecondaryOverall Survival (OS) for the First-line Treatment

Time from the date of randomization to the date of death during the entire study

Time frame:
Until death, up to 67 months
Reported as:
Median · Months
Overall Survival (OS) for the First-line Treatment
MonthsPanitumumab Plus ChemotherapyChemotherapy Alone
Overall Survival (OS) for the First-line Treatment12.9 (9.4 to 18.5)13.8 (11.8 to 22.9)
Statistical analysis
  • Panitumumab Plus Chemotherapy vs Chemotherapy Alone · Regression, Cox · p = 0.663 · Hazard ratio (hr): 1.103 · 95% CI 0.709 to 1.717Hazard ratio is presented as panitumumab plus chemotherapy:chemotherapy alone
  • Panitumumab Plus Chemotherapy vs Chemotherapy Alone · Log Rank · p = 0.666Stratified by IVRS randomization factors
SecondaryProgression Free Survival (PFS) During the Second-line Treatment Phase

The time from the first dose of panitumumab monotherapy to the date of first disease progression determined by the investigators per modified RECIST v1.0, or death within 60 days after the last evaluable tumor assessment or the second-line first dose date (whichever is later) during the second-line treatment phase.

Time frame:
Every 6 weeks until disease progression or death, up to 57 months
Reported as:
Median · Months
Progression Free Survival (PFS) During the Second-line Treatment Phase
MonthsPanitumumab Plus ChemotherapyChemotherapy Alone
Progression Free Survival (PFS) During the Second-line Treatment Phase—4.2 (1.5 to 7.6)
SecondaryOverall Response Rate (ORR) During the Second-line Treatment Phase

Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter (SLD) of target lesions from baseline; Overall Response (OR) = CR + PR. An overall response of CR or PR must be confirmed at least 4 weeks after the criteria for response are first met. ORR is the percentage of subjects with an overall response among the analysis population.

Time frame:
Every 6 weeks until disease progression or death, up to 57 months
Reported as:
Mean · Percentage of Participants
Overall Response Rate (ORR) During the Second-line Treatment Phase
Percentage of ParticipantsPanitumumab Plus ChemotherapyChemotherapy Alone
Overall Response Rate (ORR) During the Second-line Treatment Phase—13.33 (1.17 to 25.50)
SecondaryRate of Disease Control (RDC) During the Second-line Treatment Phase

Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter (SLD) of target lesions from baseline; Disease Progression (PD), \>=20% increase in the SLD of target lesions from nadir; Stable Disease (SD), Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD. An overall response of CR or PR must be confirmed at least 4 weeks after the criteria for response are first met. A best overall response of SD requires a visit response of SD or better no earlier than 35 days after the first dose date in second-line treatment. RCD is the percentage of subjects with a best overall response of CR, PR or SD among the analysis population.

Time frame:
Every 6 weeks until disease progression or death, up to 57 months
Reported as:
Mean · Percentage of Participants
Rate of Disease Control (RDC) During the Second-line Treatment Phase
Percentage of ParticipantsPanitumumab Plus ChemotherapyChemotherapy Alone
Rate of Disease Control (RDC) During the Second-line Treatment Phase—53.33 (35.48 to 71.19)
SecondaryDuration of Response (DOR) During the Second-line Treatment Phase

Time from the first CR or PR to the first observed disease progression by a modified RECIST v1.0. Subjects not meeting the criteria for progression by the analysis data cutoff date will be censored at their last evaluable disease assessment date.

Time frame:
Every 6 weeks until disease progression or death, up to 57 months
Reported as:
Median · Months
Duration of Response (DOR) During the Second-line Treatment Phase
MonthsPanitumumab Plus ChemotherapyChemotherapy Alone
Duration of Response (DOR) During the Second-line Treatment Phase—NA (5.1 to NA)
SecondaryTime to Response (TTR) During the Second-line Treatment Phase

Time from the first dose of panitumumab monotherapy to the first CR or PR during second-line treatment phase (subsequently confirmed at least 4 weeks thereafter)

Time frame:
Every 6 weeks until disease progression or death, up to 57 months
Reported as:
Mean · Weeks
Time to Response (TTR) During the Second-line Treatment Phase
WeeksPanitumumab Plus ChemotherapyChemotherapy Alone
Time to Response (TTR) During the Second-line Treatment Phase—10.6 ± 5.6
SecondaryOverall Survival (OS) for the Second-line Treatment

Time from the first dose of panitumumab monotherapy to the date of death during the entire study

Time frame:
Until death, up to 57 months
Reported as:
Median · Months
Overall Survival (OS) for the Second-line Treatment
MonthsPanitumumab Plus ChemotherapyChemotherapy Alone
Overall Survival (OS) for the Second-line Treatment—8.5 (6.5 to 13.2)

Adverse events

Collected over The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date of the first-line treatment. The median time frame is 4.5 months for Panitumumab Plus Chemotherapy arm and 4.4 months for Chemotherapy Alone arm.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Panitumumab Plus Chemotherapy—34/56 (60.7%)54/56 (96.4%)
Chemotherapy Alone—27/55 (49.1%)53/55 (96.4%)
Most frequent serious events
Showing 10 of 98
Most frequent serious events
EventPanitumumab Plus ChemotherapyChemotherapy Alone
DehydrationMetabolism and nutrition disorders8/562/55
PneumoniaInfections and infestations4/566/55
DiarrhoeaGastrointestinal disorders6/562/55
HypotensionVascular disorders5/560/55
Febrile neutropeniaBlood and lymphatic system disorders3/564/55
NauseaGastrointestinal disorders2/564/55
VomitingGastrointestinal disorders2/564/55
PyrexiaGeneral disorders2/564/55
AnaemiaBlood and lymphatic system disorders1/563/55
NeutropeniaBlood and lymphatic system disorders3/563/55
Most frequent other events
Showing 10 of 87
Most frequent other events
EventPanitumumab Plus ChemotherapyChemotherapy Alone
NauseaGastrointestinal disorders34/5633/55
FatigueGeneral disorders28/5628/55
AnaemiaBlood and lymphatic system disorders22/5627/55
DiarrhoeaGastrointestinal disorders25/5616/55
HypomagnesaemiaMetabolism and nutrition disorders23/5613/55
RashSkin and subcutaneous tissue disorders21/562/55
Decreased appetiteMetabolism and nutrition disorders20/5610/55
VomitingGastrointestinal disorders15/5618/55
AlopeciaSkin and subcutaneous tissue disorders18/5614/55
HypokalaemiaMetabolism and nutrition disorders17/566/55

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Panitumumab Plus ChemotherapyChemotherapy AloneTotal
Mean58.2 ± 8.658.9 ± 7.458.6 ± 8.0
Sex: Female, Male
Sex: Female, Male(Participants)Panitumumab Plus ChemotherapyChemotherapy AloneTotal
Female9514
Male475299
08

Study locations

114 sites
  • Research Site
    Tucson, Arizona 85715, United States
  • Research Site
    Jonesboro, Arkansas 72401, United States
  • Research Site
    Duarte, California 91010, United States
  • Research Site
    La Jolla, California 92037, United States
  • Research Site
    La Verne, California 91750, United States
  • Research Site
    Los Angeles, California 90095, United States
  • Research Site
    Santa Cruz, California 95065, United States
  • Research Site
    Aurora, Colorado 80045, United States
  • Research Site
    Denver, Colorado 80210, United States
  • Research Site
    Norwich, Connecticut 06360, United States
  • Research Site
    Newark, Delaware 19713, United States
  • Research Site
    Washington, District of Columbia 20007, United States
  • Research Site
    Washington, District of Columbia 20010, United States
  • Research Site
    Washington, District of Columbia 20037, United States
  • Research Site
    Washington, District of Columbia 20422, United States
  • Research Site
    Lakeland, Florida 33805, United States
  • Research Site
    Miami, Florida 33176, United States
  • Research Site
    New Port Richey, Florida 34655, United States
  • Research Site
    Orlando, Florida 32806, United States
  • Research Site
    Athens, Georgia 30607, United States
  • Research Site
    Griffin, Georgia 30224, United States
  • Research Site
    Marietta, Georgia 30060, United States
  • Research Site
    Centralia, Illinois 62801, United States
  • Research Site
    Elk Grove Village, Illinois 60007, United States
  • Research Site
    Evanston, Illinois 60201, United States
  • Research Site
    Park Ridge, Illinois 60068, United States
  • Research Site
    Zion, Illinois 60099, United States
  • Research Site
    Wichita, Kansas 67214, United States
  • Research Site
    Ashland, Kentucky 41101, United States
  • Research Site
    Lexington, Kentucky 40536, United States
  • Research Site
    Louisville, Kentucky 40202-1703, United States
  • Research Site
    Louisville, Kentucky 40202, United States
  • Research Site
    Paducah, Kentucky 42003, United States
  • Research Site
    Baltimore, Maryland 21204, United States
  • Research Site
    Baltimore, Maryland 21237, United States
  • Research Site
    Frederick, Maryland 21701, United States
  • Research Site
    Boston, Massachusetts 02114, United States
  • Research Site
    Ann Arbor, Michigan 48106-0995, United States
  • Research Site
    Lansing, Michigan 48910, United States
  • Research Site
    Pascagoula, Mississippi 39581, United States
  • Research Site
    Columbia, Missouri 65201, United States
  • Research Site
    Jefferson City, Missouri 65109, United States
  • Research Site
    Saint Louis, Missouri 63110-1093, United States
  • Research Site
    Saint Louis, Missouri 63110, United States
  • Research Site
    Billings, Montana 59102, United States
  • Research Site
    Omaha, Nebraska 68114, United States
  • Research Site
    Henderson, Nevada 59074, United States
  • Research Site
    Hackensack, New Jersey 07601, United States
  • Research Site
    Binghamton, New York 13905, United States
  • Research Site
    Bronx, New York 10457, United States
  • Research Site
    Bronx, New York 10467, United States
  • Research Site
    Mineola, New York 11501, United States
  • Research Site
    New York, New York 10003, United States
  • Research Site
    New York, New York 10032, United States
  • Research Site
    Nyack, New York 10960, United States
  • Research Site
    Rochester, New York 14623, United States
  • Research Site
    Syracuse, New York 13210, United States
  • Research Site
    Canton, Ohio 44718, United States
  • Research Site
    Cincinnati, Ohio 45236, United States
  • Research Site
    Dayton, Ohio 45420, United States
  • Research Site
    Toledo, Ohio 43614, United States
  • Research Site
    Oklahoma City, Oklahoma 73104, United States
  • Research Site
    Langhorne, Pennsylvania 19047, United States
  • Research Site
    Philadelphia, Pennsylvania 19107, United States
  • Research Site
    Scranton, Pennsylvania 18510, United States
  • Research Site
    Charleston, South Carolina 29406, United States
  • Research Site
    Charleston, South Carolina 29425, United States
  • Research Site
    Greenville, South Carolina 29615, United States
  • Research Site
    Memphis, Tennessee 38120, United States
  • Research Site
    Arlington, Texas 76012, United States
  • Research Site
    Corpus Christi, Texas 78405, United States
  • Research Site
    Corpus Christi, Texas 78412, United States
  • Research Site
    Dallas, Texas 75201, United States
  • Research Site
    Dallas, Texas 75230, United States
  • Research Site
    Dallas, Texas 75234, United States
  • Research Site
    Galveston, Texas 77555-0158, United States
  • Research Site
    San Antonio, Texas 78229, United States
  • Research Site
    Abingdon, Virginia 24211, United States
  • Research Site
    Chesapeake, Virginia 23320, United States
  • Research Site
    Morgantown, West Virginia 26506, United States
  • Research Site
    Madison, Wisconsin 53792, United States
  • Research Site
    Marshfield, Wisconsin 54449, United States
  • Research Site
    Graz, 8036, Austria
  • Research Site
    Leoben, 8700, Austria
  • Research Site
    Linz, 4010, Austria
  • Research Site
    Wien, 1090, Austria
  • Research Site
    Brasschaat, 2930, Belgium
  • Research Site
    Brugge, 8000, Belgium
  • Research Site
    Kortrijk, 8500, Belgium
  • Research Site
    Libramont, 6800, Belgium
  • Research Site
    Liege, 4000, Belgium
  • Research Site
    Ottignies, 1340, Belgium
  • Research Site
    Wilrijk, 2610, Belgium
  • Research Site
    Brno, 656 53, Czechia
  • Research Site
    Praha 5, 150 06, Czechia
  • Research Site
    Znojmo, 669 02, Czechia
  • Research Site
    Angers, 49933, France
  • Research Site
    Lens cedex, 62307, France
  • Research Site
    Perpignan, 66000, France
  • Research Site
    Vandoeuvre les Nancy, 54511, France

Showing the first 100 of 114 sites across 9 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Wirth LJ. PARTNER: a study of panitumumab plus chemotherapy for first-line treatment of advanced head and neck cancer. Commun Oncol. 2008;5(Supp 14):1-4.
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2007 to primary completion in Jun 2012, 65 months.

Results were first posted in Feb 2014, 1 year 7 months after primary completion. A results delay was requested in Aug 2011.

Of 88 industry-sponsored phase 2 interventional studies under Neoplasm Metastasis, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 63. This study's 65 months is above that.

Counting every sponsor, half of 443 studies reached it within 56 months; a quarter within 33 and three quarters within 83.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 29, 2007
First posted
Apr 2, 2007
StartActual
Jan 1, 2007
Primary completionActual
Jun 11, 2012
CompletionActual
Jan 1, 2014
Results delay requested
Aug 16, 2011
Results first posted
Feb 7, 2014
Last update
Oct 17, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 17, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00454779
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Apr 2, 2007
Start date
Jan 1, 2007
Primary completion
Jun 11, 2012
Completion
Jan 1, 2014
Results posted
Feb 7, 2014
Last update
Oct 17, 2018

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Panitumumab

Start the discussion